• RESTORE is evaluating NVG-291’s potential to improve hand function and quality of life in individuals living with chronic cervical motor-incomplete spinal cord injury
• Study builds on functional improvements observed in the placebo-controlled Phase 1b/2a CONNECT SCI study, with FDA alignment on the Phase 3 registrational design
• Enrollment completion anticipated in the second half of 2027; topline data expected in the first half of 2028
   

MIAMI, Oct. 12, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ:NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that the first participant has been dosed in RESTORE, a Phase 3 registrational study evaluating NVG-291 in individuals living with chronic cervical motor-incomplete SCI. NervGen anticipates completing enrollment in the second half of 2027 and reporting topline data in the first half of 2028.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.